Amneal Pharmaceuticals’ (AMRX) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.

Amneal Pharmaceuticals (NASDAQ:AMRX)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $22.00 price target on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 22.46% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, August 12th. Barclays raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. UBS Group upped their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded up $0.04 during trading hours on Wednesday, reaching $17.96. The company’s stock had a trading volume of 148,459 shares, compared to its average volume of 2,126,266. The firm’s 50 day simple moving average is $17.59 and its 200-day simple moving average is $14.79. The company has a market capitalization of $5.74 billion, a price-to-earnings ratio of 36.70 and a beta of 1.27. Amneal Pharmaceuticals has a fifty-two week low of $9.20 and a fifty-two week high of $19.26. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Sell-side analysts forecast that Amneal Pharmaceuticals will post 0.94 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, EVP Jason B. Daly sold 210,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its position in Amneal Pharmaceuticals by 5.3% in the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after acquiring an additional 624,609 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after acquiring an additional 81,546 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the period. Nantahala Capital Management LLC lifted its holdings in shares of Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after purchasing an additional 558,877 shares during the period. Finally, State Street Corp grew its stake in shares of Amneal Pharmaceuticals by 3.4% in the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after purchasing an additional 136,662 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.